gsk-5498a and Arthritis--Rheumatoid

gsk-5498a has been researched along with Arthritis--Rheumatoid* in 1 studies

Other Studies

1 other study(ies) available for gsk-5498a and Arthritis--Rheumatoid

ArticleYear
Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro-
    Journal of medicinal chemistry, 2021, 12-09, Volume: 64, Issue:23

    The role of calcium release-activated calcium (CRAC) channels is well characterized and is of particular importance in T-cell function. CRAC channels are involved in the pathogenesis of several autoimmune diseases, making it an attractive therapeutic target for treating inflammatory diseases, like rheumatoid arthritis (RA). A systematic structure-activity relationship study with the goal of optimizing lipophilicity successfully yielded two lead compounds,

    Topics: Administration, Oral; Animals; Area Under Curve; Arthritis, Rheumatoid; Calcium; Calcium Channel Blockers; Calcium Release Activated Calcium Channels; Clinical Trials, Phase I as Topic; Drug Discovery; Humans; Jurkat Cells; Male; Mice; Mice, Inbred BALB C; Rats; Rats, Inbred Lew; Structure-Activity Relationship

2021